Disclosure of Erlotinib as a Multikinase Inhibitor in Pancreatic Ductal Adenocarcinoma

A placebo-controlled phase 3 trial demonstrated that the epidermal growth factor receptor (EGFR) inhibitor erlotinib in combination with gemcitabine was especially efficient in a pancreatic ductal adenocarcinoma (PDAC) subgroup of patients developing skin toxicity. However, EGFR expression was not p...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Conradt, Laura, Godl, Klaus, Schaab, Christoph, Tebbe, Andreas, Eser, Stefan, Diersch, Sandra, Michalski, Christoph W, Kleeff, Jörg, Schnieke, Angelika, Schmid, Roland M, Saur, Dieter, Schneider, Günter
Formato: Artigo
Lenguaje:Inglês
Publicado: Neoplasia Press Inc. 2011
Materias:
Research Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC3223607/
https://ncbi.nlm.nih.gov/pubmed/22131878
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares